Skip to main content
Premium Trial:

Request an Annual Quote

NCI to Fund Small Businesses Developing Molecular Analysis Tools

NEW YORK (GenomeWeb News) – The National Cancer Institute plans to fund small businesses undertaking projects to develop new molecular or cellular analysis tools for use in cancer research and clinical care, according to a new funding announcement.

These Small Business Innovation Research grants will fund R&D projects under NCI's Innovative Molecular Analysis Technology (IMAT) program, which supports early-stage development and validation of high-risk, high-payoff tools that improve the molecular or cellular analysis of cancer.

These SBIR grants will provide small businesses with up to $150,000 for Phase I projects and up to $1 million for Phase II efforts, although in certain cases these awards may go as high as $225,000 for Phase I and $1.5 million for Phase II projects, if there is appropriate justification.

The IMAT program launched in 1998 with the aim of advancing the development of tools that will improve molecular and cellular analysis of cancer in both the lab and the clinic.

This new funding will support those goals by helping to ease the path toward commercialization of technologies that offer significant advantages over methods, tools, and approaches that are currently available.

The technology areas NCI wants these grants to support include tools for deciphering the mechanisms underlying cancer initiation and progression; for improving early cancer detection and risk assessment; for distinguishing, assessing, or monitoring cancer progression; for facilitating drug development; for enhancing molecular analyses in cancer epidemiology; for assessing general analyte quality; for preparing and processing samples; and for overcoming barriers in research.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.